Published in

Taylor and Francis Group, Artificial Cells, Blood Substitutes and Biotechnology, 1-2(40), p. 1-6

DOI: 10.3109/10731199.2011.560120

Links

Tools

Export citation

Search in Google Scholar

Microencapsulated mammalian cells for simultaneous production of VEGF165b and IFNα

Journal article published in 2012 by Fatemeh Afkhami, Yves Durocher, Satya Prakash
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Targeted and simultaneous delivery VEGF165b and IFN alpha in anti-angiogenic and other applications could offer several advantages. For this a system was design using artificial cell alginate-poly-L-lysine- alginate (APA) microcapsules. Result confirms the ability of this system for simultaneous production of these proteins for 28-days. The IFN alpha on a 3 days period increased from 8 ± 0.36 μg/ml at day 10 to 27 ± 2.4 μg/ml at day 16 and then dropped to 6.5 ± 0.5 μg/ml. The VEGF165b on a 3 days period increased from 2.7 ± 0.7 μg/ml at day 10 to 6.9 ± 1 μg/ml at day 16. ; peer reviewed: yes ; NRC Pub: yes